Capricor Therapeutics

CAPR · NASDAQ

$6.61−$0.04 (−0.60%)TodayMarket closed · Oct 20, 7:56 PM ET

Prev close $6.65

CAPR analyst rating

BuyConsensus of 8 analysts over the last 12 months. 75% rate it a buy.

Strong buy0
Buy6
Hold2
Underperform0
Sell0

12-month price target · 8 analysts

Average $24.14 (+265.2% upside)

Low: $7.07
Now: $6.61
High: $56.70

Upgrades and downgrades

The latest rating actions, newest first

CAPR analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
B. Riley Securities	Sep 14, 2026	Upgrade	Neutral → Buy	$5.00 → $21.00	30%
Piper Sandler	Sep 1, 2026	Upgrade	Neutral → Overweight	$2.00 → $25.00	40%
Cantor Fitzgerald	Aug 14, 2026	Upgrade	Neutral → Overweight	$3.50 → $28.00	41%
Jones Trading	Jul 31, 2026	Downgrade	Buy → Hold	—	21%
Piper Sandler	Jul 30, 2026	Downgrade	Overweight → Neutral	$58.00 → $2.00	40%
Cantor Fitzgerald	Jul 30, 2026	Downgrade	Overweight → Neutral	$62.00 → $3.50	41%
HC Wainwright & Co.	Jul 30, 2026	Downgrade	Buy → Neutral	—	40%
HC Wainwright & Co.	May 13, 2026	Maintains	Buy	$60.00	40%
B. Riley Securities	Mar 13, 2026	Maintains	Buy	$50.00 → $63.00	30%
Piper Sandler	Mar 13, 2026	Maintains	Overweight	$45.00 → $58.00	40%

The case for and against

Updated Oct 21, 2026

Bull case

Capricor Therapeutics is viewed favorably because deramiocel has a credible late-stage catalyst profile, with the FDA accepting the major BLA amendment and extending the PDUFA to November 22nd, while open-label extension data and the HOPE-3 Lancet publication reinforce the case for upper-limb benefit in DMD. The investment case is further strengthened by measurable clinical evidence, including a 4.55% treatment difference in PUL 2.0 versus placebo at 12 months and a supportive 24-month dataset, which may improve approval odds despite the negative CTGTAC vote on cardiomyopathy. Financially, the company’s $238 million of cash at 2Q:26, potential warrant proceeds of $19.1 million, and an estimated $797 million 2030E U.S. net revenue share underpin a large asymmetric opportunity that could re-rate the stock.

Bear case

Capricor Therapeutics is a clinical-stage biotech with a highly concentrated thesis on deramiocel, and the data remain vulnerable to interpretation because the placebo crossover benefit in HOPE-2-OLE could be confounded by dropouts, imputation, or a natural-history reversion toward the -2.7/yr slope. The company also faces meaningful regulatory uncertainty after the recent AdCom on 7/29/26, and the FDA may still judge the dataset insufficient for approval, which would jeopardize the expected near-term non-dilutive cash infusion of >$230M. Beyond the clinic, litigation with its U.S. commercialization partner, outsourced commercialization control, and the need for additional capital if the launch or approval path slows all raise dilution and execution risk for a company with an early-stage, limited pipeline.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.